Abcam Competitors and Similar CompaniesClear all
Abcam's competitors and similar companies include BioLegend, Humanigen and LGC.
 Abcam Abcam is a life sciences company that identifies and develops biological, protein, and custom cell engineering tools. |  Humanigen Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. | |||
Founding Date | Founding Date 1998 | Founding Date 2002 | Founding Date 2000 | Founding Date 1842 |
Type | Type Subsidiary | Type Subsidiary | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Cambridge, GB HQ Hangzhou Shi, CN Shanghai, CN Hong Kong, HK Tokyo, JP Branford, US Burlingame, US see more | Locations San Diego, US HQ Beijing, CN Tokyo, JP | Locations Burlingame, US HQ Dublin, IE London, GB Kansas City, US | Locations Guildford, GB HQ São José Dos Campos, BR Sofia, BG Milton, CA Pointe Claire, CA Vaughan, CA Beijing, CN see more |
Employees | Employees 6355% decrease | Employees 6571% decrease | Employees 233% decrease | Employees 9465% increase |
Financial | ||||
Revenue (est.) | Revenue (est.) £236m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $2.5m (FY, 2022) | Revenue (est.) £165.1m (FY, 2025) |
Cost of goods | Cost of goods £116.9m (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods £111m (FY, 2025) |
Gross profit | Gross profit £119.1m (FY, 2024) | Gross profit N/A | Gross profit N/A | Gross profit £54.1m (FY, 2025) |
Net income | Net income £132.9m (FY, 2024) | Net income N/A | Net income ($70.7m) (FY, 2022) | Net income £13.9m (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 79.6m | Total funding raised N/A | Total funding raised $ 131.7m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
BioLegend
HQ
San Diego, US
BioLegend is a company that develops and manufactures antibodies and reagents.
View companyHumanigen
HQ
Burlingame, US
Employees
2↓ 33% decrease
Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.
View company